Giant Cells Glioblastoma: Case Report and Pathological Analysis from This Uncommon Subtype of Glioma

Glioblastoma multiforme (GBM) is the most common glial tumor of the brain system; nevertheless, the giant cell (GC) subtype is uncommon. Recent reviews report for an incidence of 1% in adults and 3% in children. The GCs usually have a better prognosis than GBM and also an increasing long-term surviv...

Descripción completa

Detalles Bibliográficos
Autores principales: Belsuzarri, Telmo A.B., Araujo, João F.M., Catanoce, Aguinaldo P., Neves, Maick W.F., Sola, Rodrigo A.S., Navarro, Juliano N., Brito, Leandro G., Silva, Nilton R., Pontelli, Luis Otavio C., Mattos, Luiz Gustavo A., Gonçales, Tiago F., Zeviani, Wolnei M., Marques, Renata M.B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4387352/
https://www.ncbi.nlm.nih.gov/pubmed/25918606
http://dx.doi.org/10.4081/rt.2015.5634
Descripción
Sumario:Glioblastoma multiforme (GBM) is the most common glial tumor of the brain system; nevertheless, the giant cell (GC) subtype is uncommon. Recent reviews report for an incidence of 1% in adults and 3% in children. The GCs usually have a better prognosis than GBM and also an increasing long-term survival rate. It is known that the diagnosis of this tumor is due to its histological findings and patterns, such as the unusual increased number of giant cells. Unfortunately, due to its rarity, the immunohistochemical and cytogenetical analysis of this tumor is not well known. Some authors also suggest that there are few subtypes of GCs and their patterns of aggressiveness could be due to cytogenetical markers. It is recognized that maximum safe resection treatment and adjuvant radiotherapy can improve survival rate (5-13 months) similar to GBM patients.

Ejemplares similares